Spinifex Pharmaceuticals has raised $6.5 million through an expanded round of series B funding. The financing round was led by GBS Venture Partners, Brandon Capital, Uniseed and UniQuest.

The company had earlier secured $12.59 million from the same syndicate. The proceeds will be used by the Australian company to fund the development of its pain management drug.

Click here for the release from PR Newswire.